Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Outlook Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Outlook Therapeutics, Inc. annual and quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Outlook Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Dec 2024 was $9,224,962, a 29% increase year-over-year.
  • Outlook Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $6,844,453, a 19% increase from 2024.
  • Outlook Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $8,464,444, a 241% decline from 2023.
  • Outlook Therapeutics, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $5,995,170, a 105% increase from 2022.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)

Outlook Therapeutics, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $6,844,453 +$1,619,991 +19% 01 Oct 2024 30 Sep 2025 10-K 19 Dec 2025 2025 FY
2024 $8,464,444 -$14,459,614 -241% 01 Oct 2023 30 Sep 2024 10-K 19 Dec 2025 2025 FY
2023 $5,995,170 +$3,075,682 +105% 01 Oct 2022 30 Sep 2023 10-K 27 Dec 2024 2024 FY
2022 $2,919,488 +$978,150 +50% 01 Oct 2021 30 Sep 2022 10-K 22 Dec 2023 2023 FY
2021 $1,941,338 -$2,579,120 -57% 01 Oct 2020 30 Sep 2021 10-K 29 Dec 2022 2022 FY
2020 $4,520,458 -$1,777,679 -28% 01 Oct 2019 30 Sep 2020 10-K 23 Dec 2021 2021 FY
2019 $6,298,137 +$7,766,265 01 Oct 2018 30 Sep 2019 10-K 23 Dec 2020 2020 FY
2018 $1,468,128 01 Oct 2017 30 Sep 2018 10-K 19 Dec 2019 2019 FY

Outlook Therapeutics, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $9,224,962 +$3,810,390 +29% 01 Oct 2024 31 Dec 2024 10-Q 14 Feb 2025 2025 Q1
Q4 2023 $13,035,352 -$47,979,388 -137% 01 Oct 2023 31 Dec 2023 10-Q 14 Feb 2025 2025 Q1
Q4 2022 $34,944,036 -$20,729,564 -37% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q1
Q4 2021 $55,673,600 +$62,641,134 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023 2023 Q1
Q4 2020 $6,967,534 -$285,565 -4.3% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q1
Q4 2019 $6,681,969 -$5,192,294 -349% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q1
Q4 2018 $1,489,675 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.